Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.
Identifieur interne : 000433 ( PubMed/Corpus ); précédent : 000432; suivant : 000434Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.
Auteurs : Calum D. Moulton ; C W P. Hopkins ; W Richard Bevan-JonesSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antidepressive Agents.
- complications : Huntington Disease.
- drug therapy : Depression.
- etiology : Depression.
- Humans.
Abstract
Depressive symptoms are common in Huntington's disease (HD), profoundly affect quality of life, and predict suicidal ideation. However, no recent review of antidepressant treatment in HD has been published.
DOI: 10.1002/mds.25980
PubMed: 25111961
Links to Exploration step
pubmed:25111961Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.</title><author><name sortKey="Moulton, Calum D" sort="Moulton, Calum D" uniqKey="Moulton C" first="Calum D" last="Moulton">Calum D. Moulton</name><affiliation><nlm:affiliation>Institute of Psychiatry, King's College London.</nlm:affiliation></affiliation></author><author><name sortKey="Hopkins, C W P" sort="Hopkins, C W P" uniqKey="Hopkins C" first="C W P" last="Hopkins">C W P. Hopkins</name></author><author><name sortKey="Bevan Jones, W Richard" sort="Bevan Jones, W Richard" uniqKey="Bevan Jones W" first="W Richard" last="Bevan-Jones">W Richard Bevan-Jones</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25111961</idno><idno type="pmid">25111961</idno><idno type="doi">10.1002/mds.25980</idno><idno type="wicri:Area/PubMed/Corpus">000433</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.</title><author><name sortKey="Moulton, Calum D" sort="Moulton, Calum D" uniqKey="Moulton C" first="Calum D" last="Moulton">Calum D. Moulton</name><affiliation><nlm:affiliation>Institute of Psychiatry, King's College London.</nlm:affiliation></affiliation></author><author><name sortKey="Hopkins, C W P" sort="Hopkins, C W P" uniqKey="Hopkins C" first="C W P" last="Hopkins">C W P. Hopkins</name></author><author><name sortKey="Bevan Jones, W Richard" sort="Bevan Jones, W Richard" uniqKey="Bevan Jones W" first="W Richard" last="Bevan-Jones">W Richard Bevan-Jones</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressive Agents (therapeutic use)</term><term>Depression (drug therapy)</term><term>Depression (etiology)</term><term>Humans</term><term>Huntington Disease (complications)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depressive symptoms are common in Huntington's disease (HD), profoundly affect quality of life, and predict suicidal ideation. However, no recent review of antidepressant treatment in HD has been published.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25111961</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>06</Day></DateCreated><DateCompleted><Year>2015</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.</ArticleTitle><Pagination><MedlinePgn>1556-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25980</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depressive symptoms are common in Huntington's disease (HD), profoundly affect quality of life, and predict suicidal ideation. However, no recent review of antidepressant treatment in HD has been published.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a PRISMA systematic review of HD studies, which used a recognized antidepressant and measured change in depressive symptoms using a validated psychiatric scale. Controlled trials, uncontrolled trials, observational studies, and case series were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven studies were included, totalling 190 patients. One study examined venlafaxine, one fluoxetine, one citalopram, one atomoxetine, one modafinil, one lithium, and five antipsychotics. No studies were of adequate duration, size, or outcome, and no controlled trial in a depressed population produced a positive result.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Inadequate evidence exists to guide antidepressant treatment in HD. Further research is needed to assess antidepressant efficacy and to examine whether treatment of depression represents a modifiable target for the high suicide rate in HD.</AbstractText><CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moulton</LastName><ForeName>Calum D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>C W P</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Bevan-Jones</LastName><ForeName>W Richard</ForeName><Initials>WR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2015 Sep;30(10):1438</RefSource><PMID Version="1">26207615</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2015 Sep;30(10):1438-9</RefSource><PMID Version="1">26010142</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006816">Huntington Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antidepressant</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">rating scale</Keyword><Keyword MajorTopicYN="N">suicidality</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25111961</ArticleId><ArticleId IdType="doi">10.1002/mds.25980</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000433 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000433 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25111961
|texte= Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25111961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |